Finding gives boost to fighting cancer through cell metabolism

Uncontrolled activation of RAS causes approximately a third of all tumors and helps cancerous cells evade anti-cancer drugs. Vanderbilt researchers have identified small molecules that target this pathway and further defined how these small molecule compounds work.

Vanderbilt-Ingram Cancer Center Ambassadors surpassed the $1 million mark with the awarding of the group’s latest research grants.

Changes in enzymes involved in lysophospholipid signaling can activate a pathway implicated in development of cancer, a recent study suggests.

Carlos F. Lopez, PhD, and colleagues propose a new “conveyor belt” mechanism for how cellular signaling is amplified, or strengthened, as signals are handed off from one enzyme to the next.

A recent study in the journal Cancer Research demonstrates that a RIG-I agonist has potent immunogenic and therapeutic effects in breast cancer.

A recent study in Nature Communications defines the in vivo substrates of RIG-I like receptors (RLRs) during an oncogenic virus infection and reveals a relationship between cellular RNA processing and an innate antiviral immune response.

Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine.

Nashville Predators goaltender Pekka Rinne, Predators executives and executives from Tri Star Energy (Twice Daily) made their annual presentation recently of proceeds from the team’s 365 Pediatric Cancer Fund to Monroe Carell Jr. Children’s Hospital at Vanderbilt.

Charles Caskey, Ph.D., has received a cancer research grant from The Mary Kay Foundation to study how focused ultrasound therapy could be an ideal helper for immunotherapy.